

AGC-International Union of Operating Engineers Local 701 Trust Funds

Physical Address: 7525 SE 24th Street, Suite 200, Mercer Island, WA 98040 • Mailing Address: PO Box 34203, Seattle, WA 98124
Phone: (866) 697-5750 or (503) 657-9740 • Fax: (503) 657-9737 • Website: www.agc-iuoe701trusts.com

Administered by
Welfare & Pension Administration Service, Inc.

August 5, 2026

TO: All Eligible Plan Participants
AGC-International Union of Operating Engineers Local 701 Health and Welfare Trust Fund

RE: Benefit Changes – Gene and Cellular Therapy

GENE AND CELLULAR THERAPY

Effective January 1, 2025, the Plan will cover FDA Approved, Medically Necessary Gene and Cellular Therapy services from a pre-authorized in-network facility/provider. Coverage is provided subject to the Plan's annual deductible, copays, coinsurance and annual coinsurance and out-of-pocket maximums. Gene and Cellular Therapy services and treatment must be pre-authorized to be covered. Coverage is subject to all other plan limitations and exclusions. This benefit requires the assistance of the Plan's medical management provider

Gene and Cellular Therapy — includes gene and cellular based therapy techniques that modify and/or use a person's genes or cells to treat or cure disease. Gene Therapy, as defined by the Plan, includes Medically Necessary gene and cellular based therapies provided by an approved Physician, Hospital or other Provider, including, but not limited to:

- Cellular immunotherapies;
- Genetically modified oncolytic viral therapy;
- Other types of cells and tissues from and for use by the same person (autologous) and cells and tissues from one person for use by another person (allogenic) for certain therapeutic conditions;
- All human gene therapy that seeks to change the function of a gene or alter the biologic properties of living cells for therapeutic use. Examples include therapies using:
 - Luxturna® (Voretigene neparvovec)
 - Zolgensma® (Onasemnogene abeparvovec-xioi)
 - Spinraza® (Nusinersen)
- Products derived from gene editing technologies, including CRISPR-Cas9;
- Oligonucleotide-based therapies. Examples include:
 - Antisense. An example is Spinraza (Nusinersen)
 - siRNA
 - mRNA
 - microRNA therapies

The Plan does not cover out-of-network cell and gene therapy services. Cell and gene therapy services are not available under the Plan's prescription drug benefit.

Administration Office

AGC-International Union of Operating Engineers Local 701 Health and Welfare Trust Fund